EUCTR2012-005805-36-GB进行中（未招募）1 期
A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation - Quazar Post Transplant
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years at the time of signing the ICD
- •2. Diagnosis of MDS or AML according to WHO classification undergoing allogeneic HSCT using MAC, NMA or RIC preparative regimens (Bacigalupo, 2009), and with either peripheral blood or bone marrow as the source of hematopoietic stem cells
- •3. At the time of allogeneic HSCT:
- •No prior allogeneic HSCT; and
- •No more than 1 antigen mismatch at HLA-A, -B, -C, -DRB1 or -DQB1 locus for either related or unrelated donor; and
- •Bone marrow blast < 20% if MDS or = 10% if AML; and
- •Peripheral blood blast = 5%
- •4. Be able to start study therapy between 42 to 84 days following allogeneic HSCT
- •5. Post transplant bone marrow blast count = 5% confirmed within 21 days prior to starting study therapy
- •6. Adequate engraftment within 14 days prior to starting study therapy:
- •ANC = 1.0 x 10*9/L without daily use of myeloid growth factor; and
- •Platelet = 75 x 10*9/L without platelet transfusion within 1 week
- •7. Adequate organ function:
- •Serum AST/SGOT and ALT/SGPT < 3 x upper limit of normal (ULN)
- •Serum bilirubin < 2 x ULN. Higher levels are acceptable if these can be attributed to active RBC precursor destruction within the bone marrow (ie, ineffective erythropoiesis) or Gilbert’s syndrome
- •Serum creatinine < 2 x ULN
- •8. Adequate coagulation (PT = 15 seconds, PTT = 40 seconds, and/or INR = 1.5)
- •9. ECOG performance status of 0, 1 or 2
- •10. Females of childbearing potential (FCBP) may participate, providing they meet the following conditions:
- •Agree to use at least two effective contraceptive methods (oral, injectable,or
- •implantable hormonal contraceptive;tubal ligation;intra-uterine device;barrier
- •contraceptive with spermicide;or vasectomized partner) throughout the study, and for 3 months following the last dose of Investigational Product; and
- •Have a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at screening; and
- •Have a negative serum or urine (investigator’s discretion) pregnancy test (sensitivity of at least 25 mIU/mL) within 72 hours prior to starting study therapy in the treatment phase (note that the screening pregnancy test can be used as the test prior to starting study therapy in the treatment phase if it is performed within the 72-hour timeframe)
- •11. Male subjects with a female partner of childbearing potential must agree to the use of at least two physician-approved contraceptive methods throughout the course of the study and should avoid fathering a child during the course of the study and for 3 months following the last dose of Investigational Product
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1. Use of any of the following after transplantation and prior to starting study therapy:
- •Chemotherapeutic agents for chemotherapy (note that prophylactic use of these agents is allowed in this study, eg, methotrexate for GVHD)
- •Investigational agents/therapies
- •Azacitidine, decitabine or other demethylating agents
- •Lenalidomide, thalidomide and pomalidomide
- •2. Active GVHD grade II or higher
- •3. Any evidence of gastrointestinal (GI) GVHD
- •4. Concurrent use of corticosteroids equivalent of prednisone at a dose > 0.5 mg/kg
- •5. Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)
- •6. Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
- •7. Prior to allogeneic HSCT, history of inflammatory bowel disease (eg, Crohn’s disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other GI disorder or defect that may interfere with the absorption, distribution, metabolism or excretion of the Investigational Product and/or predispose the subject to an increased risk of gastrointestinal toxicity
- •8. Idiopathic thrombocytopenic purpura [ITP], disseminated intravascular coagulation, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura [TTP]
- •9. Prior history of malignancies, other than MDS or AML, unless the subject has been free of the disease for = 1 year. However, subjects with the following history/concurrent conditions are allowed:
- •Basal or squamous cell carcinoma of the skin
- •Carcinoma in situ of the cervix
- •Carcinoma in situ of the breast
- •Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system)
- •10. Significant active cardiac disease within the previous 6 months, including:
- •New York Heart Association (NYHA) class III or IV congestive heart failure
- •Unstable angina or angina requiring surgical or medical intervention; and/or
- •Myocardial infarction
- •11. Known or suspected hypersensitivity to azacitidine or mannitol
- •12. Pregnant or lactating females
- •13. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
- •14. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
- •15. Any condition that confounds the ability to interpret data from the study
研究者
相似试验
招募中
1 期
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ONE TO THREE LINES OF THERAPY WHO ARE LENALIDOMIDE REFRACTORYRelapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001941-19-GRHellenic Society of Hematology (EAE)60
招募中
1 期
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat in patients with transplant ineligible newly diagnosed multiple myelomaewly diagnosed patients with multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2022-001942-39-GRHellenic Society of Hematology (EAE)36
进行中（未招募）
1 期
Belantamab Mafodotin in combination with Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who transplant ineligible.EUCTR2020-005826-27-GRHellenic Society of Hematology (EAE)66
进行中（未招募）
1 期
Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed multiple myeloma transplant ineligible.newly diagnosed multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2021-006792-42-GRHellenic Society of Hematology (EAE)36
招募中
1 期
A dose finding study of LY3884961 in patients with Gaucher diseaseType 1 Gaucher Disease (Peripheral/Non-neuronopathic Manifestations)MedDRA version: 20.0Level: PTClassification code: 10075697Term: Gaucher's disease type I Class: 100000004850CTIS2022-500281-10-02Prevail Therapeutics Inc.15